-+ 0.00%
-+ 0.00%
-+ 0.00%

Keybanc Maintains Overweight on ResMed, Lowers Price Target to $290

Benzinga·04/27/2026 14:10:43
Listen to the news
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $302 to $290.